SEC Form 5 · accession 0001611650-16-000002
Immune Therapeutics, Inc. · IMUN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Pearce
Officer — CHIEF OPERATING OFFICER · Director
Period of report
Dec 31, 2015
Accepted (ET)
Mar 30, 2016 · 6:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001559356
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCK | Sep 2, 2015 | J | 1,200,000 | $0.00 | A | 1,876,125 | D | |
| COMMON STOCK | Sep 17, 2015 | J | 1,300,000 | $0.00 | A | 1,876,125 | D | |
| COMMON STOCK | Dec 31, 2015 | J | 1,200,000 | $0.00 | D | 1,876,125 | D | |
| COMMON STOCK | Dec 31, 2015 | J | 1,300,000 | $0.00 | D | 1,876,125 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were not previously reported because they were issued in error and subsequently cancelled but should have been reported on Form 4.
- F2The shares were not previously reported because they were issued in error and subsequently cancelled but should have been reported on Form 4.
- F3The shares were issued in error and therefore are being cancelled. Both the issuance and cancellation should have been reported on Form 4.
- F4The shares were issued in error and therefore are being cancelled. Both the issuance and cancellation should have been reported on Form 4